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Abstract 
Background: The World Health Organization (WHO) recommends artemisinin combination therapy (ACT) for the 
treatment of uncomplicated Plasmodium falciparum malaria. The present study investigated the efficacy and safety of 
fixed dose combination (FDC) of arterolane maleate 37.5 mg and piperaquine phosphate (PQP) 187.5 mg dispersible 
tablets in paediatric patients aged 6 months to 12 years.
Methods: Male and female patients aged 6 months to 12 years who were confirmed cases of P. falciparum mono-
infection with fever or documented history of fever in the previous 24 h were included. The patients were admin-
istered FDC of arterolane maleate and PQP as single daily doses for three consecutive days based on their age. The 
primary efficacy outcome was proportion of patients with polymerase chain reaction (PCR)-corrected adequate 
clinical and parasitological response (ACPR) on day 28. Safety was analysed based on adverse events (AE), laboratory 
abnormalities and abnormalities on electrocardiograph.
Results: A total of 141 eligible paediatric patients received FDC of arterolane maleate and PQP in a 42-day follow-up 
study. All the enrolled patients (141) were included in intention to treat (ITT) and safety analyses, and 126 patients 
were considered in per protocol (PP) population. The PCR-corrected ACPR on day 28 was achieved in all patients 
(100 %; 95 % CI 97.11–100) included in PP population. The median parasite clearance time (PCT) and fever clearance 
time (FCT) were 24 h (95 % CI 18.0–24.0) and 10 h (95 % CI 4.0–18.0), respectively. The most frequently reported clini-
cal AE was vomiting. Majority of the AEs were mild to moderate in severity and resolved without sequelae. No patient 
was discontinued for any QTc (corrected QT interval) prolongation. No deaths or serious AEs were reported during the 
study.
Conclusion: The findings from this study showed that FDC of arterolane maleate and PQP effectively cures P. fal-
ciparum malaria and attains acceptable level of cure by day 28 in paediatric patients. The efficacy and safety results 
observed in children warrants further studies on FDC of arterolane maleate and PQP dispersible tablets.
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Background
According to the World Health Organization (WHO) 
estimates, released in December 2014, there were about 
198 million cases of malaria in 2013 and an estimated 
584,000 deaths. The burden is heaviest in the WHO Afri-
can Region, where an estimated 90 % of all malaria deaths 
occur, and in children under 5 years of age, who account 
for 78  % of all deaths [1]. Early effective treatment of 
malaria is the cornerstone of malaria control. Plasmo-
dium resistance to anti-malarial medicines is one of the 
major obstacles in the fight against malaria. Artemisinin 
combination therapy (ACT) is the WHO-recommended 
first-line treatment for uncomplicated falciparum malaria 
in all endemic regions [2, 3].
The clinical effectiveness of the artemisinin deriva-
tives in ACT is due to rapid clearance of parasitaemia 
and rapid resolution of symptoms, by reducing parasite 
numbers. However, artemisinin derivatives are derived 
from plant source, so harvesting and extraction costs 
remain variable. This leads to fluctuation in the supply 
of artemisinins [2, 5, 6]. Therefore, there exists an urgent 
need for development of novel, preferably fully synthetic 
anti-malarial drugs. Arterolane maleate is a new syn-
thetic trioxolane that is easy to synthesize, inexpensive, 
and rapidly acting oral anti-malarial drug. In ACT, arte-
misinin derivatives are used in combination with a long 
acting, more slowly eliminated partner drug that pre-
vents recrudescent infections. Piperaquine phosphate is 
a proven effective and well-tolerated anti-malarial drug. 
The tolerability, efficacy and pharmacokinetic profile and 
low cost of piperaquine phosphate make it a promising 
partner drug for use as part of ACT [4, 7, 8]. Arterolane 
maleate has been combined with piperaquine phosphate 
(long-acting anti-malarial) in a fixed dose combination.
Efficacy, safety, tolerability, and pharmacokinetics 
of arterolane maleate and piperaquine phosphate co-
administration were established in Phase I [9] and II 
studies. A phase II study assessed the anti-malarial effi-
cacy and safety of a combination of 150 mg of arterolane 
maleate and 750  mg of piperaquine phosphate in com-
parison to Coartem® (artemether-lumefantrine, AL) in 
patients with acute uncomplicated falciparum malaria. 
In this open-label, randomized, multicentric, parallel 
group, clinical trial, 240 adult patients were randomized 
to receive arterolane maleate and piperaquine phosphate 
(160 patients) or AL (80 patients). No treatment failure 
was noted in the arterolane maleate and piperaquine 
phosphate group, while one patient receiving AL was 
treatment failure on day 28. There was no difference in 
the median parasite clearance time (30 h in both groups) 
or median fever clearance time (24 h in both groups) after 
administration of the two study treatments [10]. Sub-
sequently, fixed dose combination (FDC) of arterolane 
maleate 150 mg + piperaquine phosphate 750 mg tablet 
was developed. Two phase III studies with FDC of arter-
olane maleate 150 mg + piperaquine phosphate 750 mg 
tablet have been conducted: one in adults and adolescent 
patients with falciparum malaria and another in adult 
patients with Plasmodium vivax infection. Based on effi-
cacy and safety results in these studies, FDC of arterolane 
maleate 150 mg + piperaquine phosphate 750 mg tablet 
has been approved in India for the treatment of falcipa-
rum and vivax malaria in adult patients.
Administration of ACT to infants and small children 
can be difficult and time consuming. Specially formulat-
ing anti-malarials for this vulnerable population is vital 
to ease administration and help ensure that an accurate 
dose is received. Easing administration may enhance 
adherence, improving therapeutic outcomes in infants 
and young children and preserving the efficacy of  ACT 
[11]. According to the “Guidelines for the Treatment of 
Malaria, WHO 2010” the lack of paediatric drug formula-
tions is a major impediment for the adequate treatment 
of young children as it necessitates the splitting of adult 
tablets leading to inaccurate dosing [2]. Realizing the 
need for appropriate paediatric formulation, a FDC of 
arterolane maleate 37.5  mg and piperaquine phosphate 
187.5 mg dispersible tablet has been formulated.
A comparative bioavailability study of paediatric for-
mulation, i.e., FDC of arterolane maleate 37.5  mg and 
piperaquine phosphate 187.5 mg dispersible tablet (four 
tablets) with co-administered conventional release arter-
olane maleate 150 mg (three tablets of 50 mg each) and 
piperaquine phosphate 750  mg was conducted in 48 
healthy male subjects. Based on the pharmacokinetic 
results, oral bioavailability of FDC of arterolane maleate 
37.5 mg and piperaquine phosphate 187.5 mg dispersible 
tablet was comparable to co-administered conventional 
release arterolane maleate 150 mg and piperaquine phos-
phate 750 mg in healthy, adult male subjects under fast-
ing condition.
Data from phase III studies in adults and adolescents 
have demonstrated that the FDC of arterolane maleate 
150  mg  +  piperaquine phosphate 750  mg tablet has a 
Trial Registration: Clinical Trial Registry India: CTRI/2009/091/000531
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good safety profile. Because children are the population 
primarily affected by malaria, the present phase II study 
investigated the anti-malarial efficacy and safety of FDC 
of arterolane maleate 37.5 mg and piperaquine phosphate 
187.5  mg dispersible tablets in paediatric patients with 
acute uncomplicated falciparum malaria.
Methods
Study site and enrolment
This phase II, multicentric, open-label study of 42  days’ 
duration was carried out between July 2010 to Novem-
ber 2012 at six sites across India and Africa. The patients 
were recruited from three hospitals each in India (Ispat 
General Hospital, Rourkela, Orissa; Tata Main Hospi-
tal, Jamshedpur, Jharkhand; and, Mahadevi Birla Hospi-
tal and Research Centre, Ranchi, Jharkhand) and Africa 
(General Hospital of Ayame, Ivory Coast; North Abobo 
General Hospital, Ivory Coast; and, Ruhuha Health Cen-
tre, Bugesera District, Rwanda).
Inclusion and exclusion criteria
Children of either gender aged between 6  months and 
12  years who presented with clinical symptoms of 
malaria were screened for study eligibility after assent 
was obtained from the patient (where possible) or 
informed consent from parents/guardians. Children with 
microscopically confirmed acute uncomplicated falci-
parum malaria, with parasite density ranging from 1000 
to 100,000 asexual parasites/μL (both inclusive) and an 
axillary temperature ≥37.5  °C or history of fever in the 
past 24  h, were included in the study. Additional inclu-
sion criteria were minimum body weight of 5 kg; ability 
to take drugs under study by the oral route, absence of 
severe malnutrition (defined as a child whose weight-for-
height is below −3 standard deviation or less than 70 % 
of the median of the NCHS/WHO normalized reference 
values or who had symmetrical oedema involving at least 
the feet, minimum haemoglobin level ≥8 g/dL; and, will-
ingness and ability to comply with the study protocol for 
the duration of the study; residence within a reasonable 
distance of the investigational site so that attendance of 
all study visits and follow-up by medical staff were logis-
tically feasible.
Exclusion criteria included mixed Plasmodium infec-
tion; severe malaria; presence of general danger signs 
of severe malaria among children <5  years old (as per 
WHO); infants with a history of hyperbilirubinaemia 
during the neonatal period; pregnant and lactating 
females (between the age of 8 and 12  years); ongoing 
prophylaxis with drugs having anti-malarial activity, such 
as cotrimoxazole, for the prevention of Pneumocystis 
carinii pneumonia in children born to HIV  +  women; 
any anti-malarial treatment during 1  month prior to 
screening; use of concomitant medications that could 
induce haemolysis or haemolytic anaemia from the 
WHO list of essential drugs; known allergy to artesunate, 
artemether, artemisinin-derived products, piperaquine 
phosphate or any other related drug; and, participation 
in any investigational drug study during 30  days prior 
to screening. Patients with electrocardiogram (ECG) 
abnormalities with clinical significance or relevance 
that required urgent management were excluded from 
the study. These abnormalities included QTc inter-
val  >450  ms at screening and cardiac conduction disor-
ders, with the exception of right bundle branch block. 
Patients with known significant renal or hepatic impair-
ment indicated by the following laboratory evaluations 
at screening: serum creatinine >1.5 × upper limit of nor-
mal (ULN), aspartate transaminase >2.5 × ULN, alanine 
transaminase  >2.5  ×  ULN and serum bilirubin  >3  mg/
dL; patients who have had a splenectomy; known his-
tory of HIV infection or other immunosuppressive dis-
orders; evidence of clinically significant cardiovascular, 
pulmonary, metabolic, gastrointestinal, neurological, or 
endocrine diseases, malignancy, or other abnormalities; 
history of epilepsy/convulsions; evidence of gastrointes-
tinal dysfunction that could alter absorption or motility 
(e.g., diarrhoea defined as >3 episodes of watery stools 
in the previous 24 h or patients who have had three epi-
sodes of vomiting within 24  h prior to screening); any 
other underlying disease that could compromise the 
diagnosis and the evaluation of the response to the study 
medication (including clinical symptoms of immunosup-
pression, tuberculosis, bacterial infection, cardiac or pul-
monary disease) were also excluded from the study.
Ethical considerations
The study was conducted as per the study protocol that 
was reviewed and approved by the Institutional Ethics 
Committees/Institutional Review Boards of the partici-
pating study sites and regulatory authorities. This clini-
cal study was conducted in accordance with the Good 
Clinical Practice, applicable regulatory requirements, 
and Declaration of Helsinki. Written informed consent 
was obtained from all parents/guardians of the patients. 
Assent was acquired from children wherever it was appli-
cable. This study is registered with Clinical Trial Registry 
India (CTRI/2009/091/000531).
Study treatments
Patients were administered FDC of arterolane maleate 
37.5 mg and piperaquine phosphate 187.5 mg dispersible 
tablets as single daily doses for three consecutive days 
based on their age (age group I, 6 months to <2 years: one 
tablet; age group II, 2  to  <6  years: two tablets; and, age 
group III, 6 to ≤12 years: 3 tablets) by the qualified staff 
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under supervision. Each tablet was dissolved in 10 mL of 
drinking water with continuous swirling. The study medi-
cation was administered irrespective of meals. If a patient 
vomited or regurgitated (for small children) within 1  h 
of receiving any dose of investigational product on any 
of the dosing days, the patient was administered a sec-
ond full dose (repeat dose). If the patient vomited again 
within 30  min of receiving the repeat dose, the patient 
was withdrawn from the study and given rescue treat-
ment. Re-dosing in case of vomiting was allowed only 
once during the study.
Clinical and laboratory procedures
Initial screening was offered to patients who presented 
with fever or history of fever and eligible patients were 
hospitalized for a treatment period of 3 days (day 0, 1 and 
2: day 0 being the first day of study medication dosing). 
Patients were discharged on day 3 and follow-up assess-
ments were done on weekly intervals up to day 42.
Physical examination, vital signs, body temperature, 
and clinical assessment were done at screening, on ther-
apy and at all follow-up visits. Body temperature was 
recorded at 6 h intervals (or adjusted to the closest pos-
sible 6  h interval to make the schedule consistent with 
routine care) following the first dose of study medication 
until temperature normalized and remained normal for 
24 h, and at every visit thereafter. A 12-lead electrocar-
diograph was performed on screening day 0, 1, 2, and on 
any unscheduled day if patient reported with fever and at 
follow up visits if ECG was abnormal.
Laboratory evaluations (haematology, biochemistry 
and urinalysis) were performed during study and at fol-
low-up visits. Clinically significant laboratory abnormali-
ties on any visit were repeated during the next follow-up 
visit or earlier, if clinically indicated. Adverse events were 
reported for the time of study medication administration 
and at all follow-up visits.
Parasitological assessments and parasite genotyping
Thick/thin blood smears were collected at the time of 
screening, pre-dose at day 0 and at 6  h intervals (or 
adjusted to the closest possible 6 h interval to make the 
schedule consistent with routine care) following first 
dose of administration until two consecutive negative 
smears were recorded, thereafter at day 3 and follow-up 
visits.
Filter paper samples for molecular marker studies [pol-
ymerase chain reaction (PCR) genotyping] were collected 
on screening and in the event of re-appearance of para-
sites, confirmed by microscopy, or on any other day if a 
patient returned with fever. PCR analysis was done at a 
central laboratory.
Drug concentration measurement
Venous blood samples were collected from each enrolled 
patient for pharmacokinetic analysis of arterolane 
maleate and piperaquine phosphate. The compounds 
were measured by LC–MS/MS methods validated as per 
US FDA Guidance for Industry: bioanalytical method 
validation, May 2001 [12]. An analysis was performed in 
compliance with Good Laboratory Practice regulations.
Outcomes
The study was conducted according to WHO guidelines 
[13]. The primary efficacy outcome was proportion of 
patients with PCR-corrected adequate clinical and para-
sitological response (ACPR) on day 28. PCR-corrected 
ACPR was defined as patients who had clearance of para-
sitaemia, irrespective of axillary temperature, without 
previously meeting any of the criteria of early treatment 
failure (ETF) or late clinical failure (LCF) or late para-
sitological failure (LPF). Secondary efficacy outcomes 
included parasite clearance time (PCT), defined as time 
in hours from the initiation of therapy until the first of 
two successive negative smears are obtained; fever clear-
ance time (FCT) defined as the time from first dosing 
until temperature normalizes (<37.5  °C) and remains 
normal for 24 h, and at every follow up visit thereafter; 
proportion of patients with PCR-uncorrected ACPR on 
day 28; proportion of patients with PCR-corrected and 
PCR-uncorrected ACPR on day 42 and the number of 
gametocytes count. Safety endpoints were adverse events 
or clinically significant changes in laboratory parameters, 
physical examination, ECG or vital signs.
Sample size determination
To have 100 evaluable patients in this study, 120 patients 
were planned to be enrolled, assuming an expected treat-
ment failure rate of 4 % (supported by another in-house 
phase II study, cure rate of ~96 %), a 5 % level of signifi-
cance and a precision of  ±4  % [10]. This was done to 
ensure that the 95  % (exact binomial) confidence inter-
val of cure rate would be between 90 and 99  %, well 
within the expected range. Additional 20  % patients 
were accounted for the dropouts during the study. 
However, while conducting the study in India, dropout 
rate of  ~30  % was experienced on account of vomiting. 
Therefore, enrolment of additional patients was allowed 
at these sites to ensure availability of adequate evaluable 
data. Accordingly, a total of 141 patients were enrolled in 
the study.
Statistical methods
The primary efficacy analysis was based on per-protocol 
population (PCR-corrected ACPR at day 28). The per-
protocol population included all patients who completed 
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a full course of study medication with a known efficacy 
endpoint and who did not violate the protocol in a way 
that might affect the efficacy analysis, i.e., the use of pro-
hibited concomitant medication, the presence of sig-
nificant disease or co-morbid illness, or major protocol 
violation. Intent-to-treat (ITT) and survival analyses 
were considered supportive. All the secondary endpoint 
(ACPR uncorrected at day 28, ACPR uncorrected/cor-
rected at day 42, PCT, and FCT) analyses were done on 
ITT population, which included all patients who received 
at least one dose of study medication.
The proportion of patients having PCR-corrected 
ACPR at day 28 was estimated using 95 % exact (Clopper-
Pearson) binomial confidence interval. The proportion 
of patients with PCR-uncorrected ACPR on day 28 and 
PCR-uncorrected ACPR at day 42 were analyzed similar 
to the primary endpoint. Time-to-event parameters (PCT 
and FCT) were assessed using survival analysis (Kaplan–
Meier method). Patients with early withdrawal or those in 
whom parasite was not cleared or had fever at 72 h were 
censored at day 7 (168 h), i.e., next follow-up visit. These 
patients were considered failures in ITT analysis. Game-
tocyte counts at different visits were summarized using 
descriptive statistics, along with proportion of patients 
with zero gametocyte. Demographic and other base-
line characteristics were summarized descriptively using 
mean, standard deviation, range, and count (%).
The safety population was defined as all patients who 
received any amount of study medication and had at least 
one assessment after dosing. The safety analyses included 
incidences of adverse events, summary statistics of labo-
ratory data and ECG findings. All the analyses were per-
formed using SAS software version 9.1.3 (SAS Institute, 
Cary, NC, USA) at 5 % two-sided level.
Results
Patient disposition, demographics and baseline 
characteristics
A total of 141 patients were enrolled in the study to 
receive FDC of arterolane maleate and piperaquine phos-
phate dispersible tablets. Seventeen patients were with-
drawn from study: 12 due to vomiting, four requested to 
be withdrawn and one was LCF at day 40; 124 patients 
completed day 42 of the study. However, 126 patients were 
considered in per-protocol population as the primary effi-
cacy analysis was performed at day 28 (Fig. 1). The patient 
population had 73 (52  %) male and 68 (48  %) female 
patients. The mean age was 5.9 ± 3.45 years (Table 1).
Clinical and parasitological outcome
All the enrolled patients (141) were included in ITT 
and safety analyses. The primary efficacy analysis (PCR-
corrected ACPR at day 28) was based on per-protocol 
population, comprised of 126 patients. All the secondary 
endpoint analyses were done on ITT population.
Uncorrected and corrected ACPR on day 28
In per-protocol population, the PCR-corrected ACPR 
on day 28 was achieved in 126 patients (100  %; 95  % 
CI 97.11–100) (Table  2). The PCR-uncorrected ACPR 
remained same as corrected ACPR in this study since 
there was no treatment failure on or before day 28.
Out of 141 patients, fifteen patients were withdrawn 
before day 28 and were considered failure. Therefore, the 
PCR corrected or uncorrected ACPR on day 28 in intent 
to treat population was achieved in 126 patients (89.36 %; 
95 % CI 83.06–93.92). The Kaplan–Meier plot at day 28 
supports 100 % PCR corrected or uncorrected response 
because all withdrawal cases were before day 28 (Fig. 2).
Parasite clearance time (PCT) and fever clearance time 
(FCT)
In the ITT population, the overall median PCT was esti-
mated to be 24.0 h (95 % CI 18.0–24.0). The median PCT 
in patients of age group I (6  months to  <2  years), age 
group II (2 to <6 years) and age group III (6 to ≤12 years) 
was estimated to be 22.0, 24.0 and 23.0  h, respectively 
(Fig. 3; Table 3).
Similarly, the overall median FCT was estimated to be 
10.0 h (95 % CI 4.0–18.0 h). The median FCT in patients 
of age group I, II and III was estimated to be 12.0, 12.0 
and 6.0 h, respectively (Fig. 4; Table 4).
Uncorrected and corrected ACPR on day 42
The uncorrected ACPR at day 42 was observed in 124 
patients (87.9 %, 95 % CI 81.40–92.82) (Table 5). Among 
the 17 cases withdrawn from the study, there was one 
case of LCF at day 40 and in PCR testing it was noted 
as re-infection. Therefore, PCR-corrected ACPR at day 
42 was 88.65  % (125/141) in ITT population at day 42. 
Similar result (88.73  %) was noted in survival analysis 
(Kaplan–Meier plot) (Fig.  2). PCR corrected or uncor-
rected ACPR at day 42 was 99.2  % (124/125; 95  % CI 
95.62–99.98) in per protocol population at day 42,
Proportion of aparasitaemic patients on day 3 (PRR ‑ 
Parasites Reduction Rate)
In ITT population, aparasitaemia was reported in 130 
patients (92.20 %) within 72 h. Parasitological data were 
not available for 11 patients due to vomiting and were 
considered as failures.
Gametocidal action
At baseline, gametocytes were reported in two out of 141 
patients. After day 7, gametocytes were not detected in 
any of the patients.
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Pharmacokinetic outcome
Plasma concentration data were available from 130 out of 
141 enrolled patients; 50 patients with intensive sampling 
and remaining 80 patients contributed to sparse sam-
pling data. The pharmacokinetic parameters for arter-
olane maleate in sparse sampling could not be reliably 
calculated through non-compartmental analysis owing 
to the limited sampling timepoints. Mean pharmacoki-
netic parameters for arterolane maleate and piperaquine 
phosphate following three-day oral administration 
from intensive sampling are presented in Table  6. The 
mean t1/2 values for arterolane maleate and piperaquine 
phosphate were 3.3 and 292.72  h, respectively. Pharma-
cokinetic results through non-compartmental analy-
sis indicated that mean exposures of arterolane maleate 
and piperaquine phosphate in children were similar 
across three different age groups in this study. Accumu-
lation for arterolane maleate was not observed following 
three-dose treatment regimes, however, accumulation 
for piperaquine phosphate was observed based on its 
longer terminal t1/2. A relationship of PCT as a function 
of Cmax of arterolane maleate was evaluated as depicted 
in Fig.  5. The distribution of PCT appeared to be fairly 
uniform which indicated that, among the patients evalu-
ated, there is no potential relationship of PCT with Cmax 
of arterolane maleate. Additionally, PCT as a function of 
arterolane maleate exposure (AUClast) was evaluated as 
shown in Fig. 6 and it appeared that arterolane maleate 
exposure levels (AUClast) of less than ~5  µg  h/mL were 
potentially sufficient to result in a PCT ranging from six 
Fig. 1 Patients’ disposition
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to 36 h. In this study, 48 patients (n = 58) on day 7 had 
mean concentration for piperaquine phosphate greater 
than 30 ng/mL.
Safety evaluation
The most frequent clinical adverse event was vomiting 
reported in 35 patients (24.8  %) (Table  7). Most of the 
adverse events (94 %) were of mild to moderate in inten-
sity. There were no deaths and serious adverse events 
reported during the course of the study.
The mean increase in QTc interval over baseline on day 
1 and day 2 were 20.3 and 21.3  ms, respectively. None 
of patients had QTc >500 ms on days 1 and 2. QTc pro-
longation was noted in 16 patients. Of these, 12 (8.5 %) 
patients had QTc >60 ms increase over baseline on day 1 
while ten (7.1 %) patients had QTc >60 ms increase over 
baseline on day 2. The increase in mean QTc from base-
line was not clinically significant as judged by investiga-
tor. None of the patients with prolonged QTc (>60  ms 
from baseline) had associated torsade de pointes or poly-
morphic ventricular tachycardia or signs/symptoms of 
serious arrhythmia and there were no withdrawals from 
the study based on QTc prolongation. A total of 6 events 
of QTc prolongation were judged as severe by the 
Table 1 Demographic and baseline clinical characteristics
SD standard deviation, Min minimum, Max maximum
FDC of arterolane maleate + piperaquine phosphate (n = 141)
Sex, n (%)
 Male 73 (52 %)
 Female 68 (48 %)
Age (6 months to ≤12 years), n 141
 Median 5.11
 Mean ± SD (min, max) 5.9 ± 3.45 (0.06, 12.11)
Age group 1 (6 months to <2 years), n 22
 Median 1.05
 Mean ± SD (min, max) 0.9 ± 0.39 (0.06, 1.11)
Age group 2 (2 to <6 years), n 49
 Median 4.00
 Mean ± SD (min, max) 3.8 ± 1.07 (2.00, 5.11)
Age group 3 (6 to ≤12 years), n 70
 Median 9.00
 Mean ± SD (min, max) 8.8 ± 1.83 (6.00,12.11)
Race, n (%)
 African 123 (87 %)
 Asian 18 (13 %)
Height (cm)
 Median 106.00
 Mean ± SD (min, max) 105.7 ± 19.24 (58.00,146.00)
Weight (kg)
 Median 17.00
 Mean ± SD (min, max) 18.5 ± 6.84 (7.00, 36.00)
Baseline axillary temperature (°C)
 Median 38.20
 Mean ± SD (min, max) 38.4 ± 0.88 (36.50, 40.50)
No. of baseline P. falciparum asexual parasites (µL−1)
 Median 44,720.00
 Mean ± SD (min, max) 45,428.6 ± 31,481.95 (1040.00, 99,860.00)
Table 2 Adequate clinical and  parasitological response 
(ACPR) at day 28 (per-protocol population)
n Success, n (%) 95 % CI
Age group 1 (6 months to <2 years) 19 19 (100.0) 82.35, 100.0
Age group 2 (2 to <6 years) 42 42 (100.0) 91.59, 100.0
Age group 3 (6 to ≤12 years) 65 65 (100.0) 94.48, 100.0
Overall age (6 months to ≤12 years) 126 126 (100.0) 97.11, 100.0
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investigator and these events resolved without sequelae 
or improved by day 14.
Haematological results were analysed for all patients 
(Table  8). There was a decrease in mean haemoglobin 
and haematocrit levels during the first 72 h of treatment 
with complete recovery to initial levels by day 42. In two 
patients, there was a clinically significant decrease in 
haemoglobin during the first 48  h, which subsequently 
increased and exceeded the baseline value by day 42. 
A rise in platelet, eosinophil, lymphocyte, monocyte 
counts, and downward trend in white blood cells, neutro-
phils was noted during the study. There were no signifi-
cant changes in the biochemical parameters during the 
course of the study other than one event of severe hyper-
kalaemia which started on day 28 and resolved without 
sequelae by day 42.
Discussion
In response to increased resistance of malaria parasites 
to conventional drugs, WHO recommends ACT for 
uncomplicated malaria treatment [2]. A new FDC of 
arterolane maleate 150  mg and piperaquine phosphate 
750 mg tablets has been approved in India for the treat-
ment of falciparum and vivax malaria in adults. A FDC 
of arterolane maleate 37.5  mg and piperaquine phos-
phate 187.5 mg dispersible tablets has been formulated 
and this study evaluated the efficacy and safety in paedi-
atric patients aged 6 months to 12 years having falcipa-
rum malaria.
The PCR-corrected ACPR on day 28 was achieved in 
100  % patients in per-protocol population in this study 
and the results accord with the high activity reported 
for other ACT in children with falciparum malaria [11, 
14–21]. The efficacy is consistent with the phase III study 
of FDC of arterolane maleate and piperaquine phosphate 
Fig. 2 Survival analysis at day 42 (PCR-uncorrected) Kaplan–Meier 
method
Fig. 3 Time to parasite clearance (PCT)—Kaplan–Meier method
Table 3 Parasite clearance time (PCT)
Overall the median PCT was estimated to be 24.0 h (18.0 to 24.0 h)
Statistical summary Age group 1  
(6 months to <2 years)
Age group 2  
(2 to <6 years)
Age group 3  
(6 to ≤12 years)
 Censored 3 (13.6 %) 7 (14.3 %) 1 (1.4 %)
Summary (excluding censored values)
 n 19 42 69
 Mean ± SD 21.5 ± 6.33 21.0 ± 6.81 21.2 ± 5.58
 Min, max 12, 36 6, 31 12, 36
Time to parasite clearance (h)
 Quartile estimate (95 % confidence interval)
  25 % 18.0 (18.0, 20.0) 18.0 (13.0, 19.0) 18.0 (NE, NE)
  50 % (median) 22.0 (18.0, 24.0) 24.0 (19.0, 24.0) 23.0 (18.0, 24.0)
  75 % 30.0 (24.0, NE) 30.0 (24.0, 31.0) 24.0 (NE, NE)
  Mean 23. 5 22.4 21.5
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tablets conducted in patients of falciparum malaria 
aged 12–65 years (PCR-corrected ACPR rates at day 28: 
99.25 %). There were no treatment failures until day 28 in 
all the three age groups in this study.
It was recommended by WHO that the proportion of 
patients with parasite clearance on day 3 currently as 
the best available indicator used in routine monitoring 
to measure Plasmodium falciparum sensitivity to arte-
misinins and the efficacy of ACT [22]. The artemisinin 
component in the FDC, arterolane maleate has been 
reported to achieve rapid parasite clearance within 3 days 
[5, 23] which is further validated by median PCT of 
24.0 h and the median FCT of 10 h in this study.
The concentrations of slowly eliminated anti-malar-
ial drugs are measured routinely on day 7 because 
this reflects the degree of drug exposure that must kill 
residual malaria parasites for an effective cure. Low 
piperaquine phosphate concentrations on day 7 are 
predictive of therapeutic failure. It has been hypoth-
esized that a concentration greater than 30  ng/mL on 
day 7 for piperaquine phosphate could be an indicator of 
low probability of recrudescence [24, 25]. In this study, 
the majority of patients on day 7 had mean concentra-
tion for piperaquine phosphate greater than 30  ng/mL. 
This indicates that concentrations of piperaquine phos-
phate following this dosage regimen in children could be 
potentially sufficient to prevent recrudescence. This is 
further substantiated by the fact that no recrudescence 
was reported at day 28 in the per protocol population in 
this study.
The piperaquine phosphate pharamacokinetic param-
eters well corroborated with the values reported in litera-
ture [25–27].
In the current study, a high incidence of vomit-
ing (24.8  %) was reported and is consistent with inci-
dence rates reported in the literature on paediatric 
patients taking anti-malarial drugs [16, 18, 19]. An inci-
dence of 20.2  % for vomiting was reported with FDC 
of artemether-lumefantrine in infants and children of 
12  years of age and below [28]. Similarly, anaemia rates 
(14.9 %) reported in this study are consistent with rates 
(up to 17.2 %) reported with other ACT in children [18, 
20].
In this study, none of patients had QTc >500  ms. 
Increase in mean QTc >60 ms from baseline was reported 
in few patients, which were not associated with Torsade 
de pointes or polymorphic ventricular tachycardia or 
signs/symptoms of serious arrhythmia and there were 
no withdrawals from the study based on QTc prolonga-
tion. Evaluation of QT interval changes is problematic 
Fig. 4 Time to fever clearance (FCT)—Kaplan–Meier method
Table 4 Fever clearance time (FCT)




Age group 1  
(6 months  
to <2 years)
Age group 2  
(2 to <6 years)
Age group 3  
(6 to ≤12 years)
 Censored 3 (13.6 %) 6 (12.2 %) 3 (4.3 %)
Summary (excluding censored values)
 n 19 43 67
 Mean ± SD 12.9 ± 9.37 9.1 ± 8.63 9.1 ± 7.86
 Min, max 0, 36 0, 25 0, 30
Time to fever clearance (h)
 Quartile estimate (95 % confidence interval)
  25 % 6.0 (6.0, 12.0) 0.0 (0.0, 6.0) 4.0 (0.0, 6.0)
  50 % (median) 12.0 (6.0, 19.0) 12.0 (6.0, 18.0) 6.0 (6.0, 12.0)
  75 % 24.0 (12.0, NE) 18.0 (18.0, 24.0) 18.0 (12.0, 18.0)
  Mean 16.0 11.0 10.0
Table 5 PCR uncorrected adequate clinical and  parasito-
logical response (ACPR) at day 42 (intention to treat popu-
lation)
Arterolane maleate  
and piperaquine phosphate
95 % CI
Overall Age (6 months to ≤12years) (n = 141)
 Success, n (%) 124 (87.9) (81.40, 92.82)
Age group 1 (6 months to <2years) (n = 22)
 Success, n (%) 19 (86.4) (65.09, 97.09)
Age group 2 (2 to <6years) (n = 49)
 Success, n (%) 42 (85.7) (72.76, 94.06)
Age group 3 (6 to ≤12 years) (n = 70)
 Success, n (%) 63 (90.0) (80.48, 95.88)
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in malaria because of systematic differences between the 
acute febrile admission before anti-malarial drugs are 
given and early convalescence. At presentation, patients 
are usually anxious, fasting and febrile with increased 
autonomic tone and a raised heart rate. This contrasts 
with the relaxed fed, supine, afebrile state 3  days later 
when most anti-malarial treatments are completed and 
anti-malarial concentrations are at the highest. It has 
been argued that this systematic reduction in sympa-
thetic activity with recovery leads to a consistent increase 
in the QT interval, which has been mistakenly ascribed 
to anti-malarial drug effects. It has been reported in the 
literature that QTc prolongation of  >60  ms was within 
the bounds of normal daily variation in the QTc (up to 
75–100 ms) [29, 30].
Most adverse events were mild to moderate in inten-
sity, with gastrointestinal symptoms being most fre-
quently reported clinical adverse events. There were no 
deaths and serious adverse events reported during the 
course of the study. The safety profile in this study well 
corroborated with that reported in published literature 
in patients with malaria [31–35]. Despite the relatively 
modest number of patients that this study considered, it 
is reassuring that no safety concerns occurred during the 
study.
Conclusion
The findings from this study showed that FDC of arter-
olane maleate and piperaquine phosphate effectively 
cures falciparum malaria and attains acceptable level of 
cure by day 28 in paediatric patients. The efficacy and 





AUClast (ng h/mL) AUC48-72 (ng h/mL) t1/2 (h)
n 50 50 48 26
Arterolane maleate AM 90.68 1507.93 688.29 3.30
Median 83.65 1209.30 615.25 3.24
Minimum 23.38 110.74 137.71 2.04
Maximum 204.96 6174.14 1696.75 5.48
n 50 50 48 48
Piperaquine phosphate AM 578.97 58,472.41 7333.04 292.72
Median 497.77 50,453.06 6417.42 221.48
Minimum 58.71 965.76 2337.00 94.60
Maximum 1604.18 169,956.99 20,590.96 801.86
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Fig. 5 Parasite clearance time as a function of Cmax of arterolane 
maleate

















Fig. 6 Parasite clearance time as a function of arterolane maleate 
exposure (AUClast)
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safety results observed in children warrants further stud-
ies with larger population on FDC of arterolane maleate 
and piperaquine phosphate dispersible tablets.
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